# ‘Scromiting’ Can Happen With Frequent Cannabis Use. What Are the Symptoms? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/scromiting-can-happen-with-frequent-cannabis-use-what-are-the-symptoms/ > **Published:** 2026-08-14T17:10:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:16:35-04:00 > **Clinical Summary:** Cannabinoid hyperemesis syndrome symptoms in frequent cannabis users: clinical diagnosis, mechanism, and evidence-based management for clinicians. --- ✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. THCSafetyResearchMental HealthNeurologyDosingAnxiety Why This Matters Clinicians need to recognize [cannabis hyperemesis syndrome](https://cedclinic.com/remediated-cannabis-mold-contamination-risks/) (characterized by cyclic vomiting, abdominal pain, and compulsive hot bathing) as a legitimate withdrawal condition that can occur with frequent [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), particularly with high-potency products. Understanding that symptom onset varies by cannabis type helps providers differentiate CHS from other gastrointestinal disorders and avoid unnecessary diagnostic testing and interventions. Patients should be counseled about this risk during history-taking and informed that cessation is the definitive treatment, enabling earlier diagnosis and symptom resolution. Clinical Summary [Cannabis hyperemesis syndrome](https://cedclinic.com/remediated-cannabis-mold-contamination-risks/) (CHS), colloquially termed “scromiting” due to the violent nature of the associated vomiting, is an emerging clinical entity characterized by cyclic nausea, vomiting, and compulsive hot bathing that occurs with chronic high-frequency [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). Recent research published in Cannabis and [Cannabinoid Research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) suggests that the specific type of cannabis consumed (such as flower versus concentrates, or varying [cannabinoid profiles](https://cedclinic.com/cannabis-clinical-trials-mental-health-march-2026/)) may influence the onset and severity of CHS symptoms, with some evidence indicating that higher-potency products may precipitate the condition more rapidly. Clinicians should maintain a high index of suspicion for CHS in patients presenting with chronic intractable nausea and vomiting who report regular [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/), as the diagnosis is often missed or delayed due to limited awareness among healthcare providers. Recognition of CHS is particularly important given that standard antiemetic medications are often ineffective, and the primary treatment remains complete cannabis cessation. Patients with frequent cannabis use who develop cyclic vomiting and compulsive bathing behaviors should be counseled about their specific product choices and the potential risk these pose for developing this syndrome. Dr. Caplan’s Take “Cannabinoid hyperemesis syndrome is a real clinical entity we’re seeing more frequently in heavy cannabis users, and the early signals suggest that product potency and consumption patterns may influence symptom onset, though we need larger prospective studies to establish clear dose-response relationships and identify which patients are most vulnerable.” Clinical Perspective 💊 [Cannabis hyperemesis syndrome](https://cedclinic.com/remediated-cannabis-mold-contamination-risks/), characterized by severe cyclic vomiting and compulsive bathing behaviors in chronic users, represents an underrecognized clinical entity that warrants increased provider awareness given rising cannabis potency and consumption frequency. While the syndrome’s pathophysiology remains incompletely understood, emerging evidence suggests that cannabinoid concentration and consumption patterns may influence symptom onset and severity, though individual genetic susceptibility and concurrent substance use likely confound these associations. Clinicians should maintain a high index of suspicion for CHS in patients presenting with recurrent nausea and vomiting refractory to standard antiemetics, particularly those with documented regular cannabis use, and should screen for the characteristic compulsive bathing behavior that often accompanies severe episodes. Currently, cessation remains the only definitive treatment, making it essential to counsel patients about this risk during shared decision-making regarding cannabis use, while acknowledging that symptom severity may not 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%27Scromiting%27%20Can%20Happen%20With%20Frequent%20Cannabis%20Use.%20What%20Are%20the%20Symptoms%3F%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73406)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73406)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%27Scromiting%27%20Can%20Happen%20With%20Frequent%20Cannabis%20Use.%20What%20Are%20the%20Symptoms%3F%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73406)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://www.verywellhealth.com/what-is-scromiting-from-cannabis-12057506](https://www.verywellhealth.com/what-is-scromiting-from-cannabis-12057506) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).